Last C$1.25 CAD
Change Today 0.00 / 0.00%
Volume 18.4K
As of 3:02 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

bellus health inc (BLU) Snapshot

Open
C$1.24
Previous Close
C$1.25
Day High
C$1.28
Day Low
C$1.24
52 Week High
07/28/14 - C$1.34
52 Week Low
08/21/13 - C$0.34
Market Cap
59.3M
Average Volume 10 Days
15.2K
EPS TTM
C$-0.30
Shares Outstanding
47.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BELLUS HEALTH INC (BLU)

Related News

No related news articles were found.

bellus health inc (BLU) Related Businessweek News

No Related Businessweek News Found

bellus health inc (BLU) Details

BELLUS Health Inc., together with its subsidiaries, focuses on the research and development of pharmaceutical drug candidates. The company’s lead program is KIACTA, which is in Phase III clinical trial for the treatment of AA amyloidosis. Its clinical stage drug candidate is Shigamab, a monoclonal antibody therapy for the treatment of hemolytic uremic syndrome related to shiga toxin-producing E. coli bacterial infections. The company also has an agreement with AmorChem Holdings Inc. to develop drug candidates for the treatment of AL amyloidosis. It has a strategic partnership with Auven Therapeutics for the development of KIACTA and Pharmascience. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Founded in 1993

bellus health inc (BLU) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$315.9K
Vice President of Finance
Total Annual Compensation: C$170.7K
Senior Vice President of Drug Development
Total Annual Compensation: C$321.8K
Vice President of Business Development
Total Annual Compensation: C$175.0K
Compensation as of Fiscal Year 2013.

bellus health inc (BLU) Key Developments

BELLUS Health Reports Consolidated Results for Second Quarter Ended June 30, 2014

BELLUS Health Inc. reported consolidated earnings results for second quarter ended June 30, 2014. For the quarter, the company’s revenues were CAD 420,000 against CAD 383,000 a year ago. Net loss attributable to shareholders was CAD 737,000 against CAD 867,000 a year ago. Basic and diluted loss per share was CAD 0.02 against CAD 0.02 a year ago. Revenues mainly consist of revenue recognized for accounting purposes from the asset sale and license agreement and the service agreement entered into with Auven Therapeutics in 2010 in relation to KIACTA(TM). Net finance income amounted to CAD 28,000 for the three-month period ended June 30, 2014, compared to CAD 104,000 for the corresponding period the previous year.

BELLUS Health Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 03:30 PM

BELLUS Health Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 03:30 PM. Venue: Toronto Board of Trade, 1 First Canadian Place (Corner of Bay and Adelaide), Toronto, ON M5X 1C1, Canada.

Auven Therapeutics and BELLUS Health Provide Update on the KIACTATM Phase III Confirmatory Study in AA Amyloidosis

Auven Therapeutics and BELLUS Health Inc. announced that the KIACTATM Phase III Confirmatory Study in AA amyloidosis (an orphan indication) has completed its targeted enrollment of 230 patients. Eligible patients currently in screening will also be given the opportunity to enroll in the study likely increasing total recruitment beyond 230 patients. The Phase III Confirmatory Study is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of KIACTATM in preventing renal function decline in patients with AA amyloidosis, which results in chronic renal failure, dialysis and death. The objective of the study is to confirm the safety and efficacy shown in a previously conducted Phase II/III study. The study is an event-driven clinical trial that will conclude when 120 patients have experienced an event linked to deterioration of kidney function. To date, over 60 patients have had an event. Based on the current event rate, the KIACTATM Phase III Confirmatory Study is expected to be completed in 2016. KIACTATM is an orally bioavailable small molecule intended for the treatment of AA amyloidosis, an orphan indication that often leads to dialysis and death. KIACTATM was originally developed by BELLUS Health.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLU:CN C$1.25 CAD 0.00

BLU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amorfix Life Sciences Ltd C$0.28 CAD 0.00
Eli Lilly & Co $62.01 USD -0.15
Novartis AG SFr.81.15 CHF +0.30
Pfizer Inc $28.89 USD -0.05
View Industry Companies
 

Industry Analysis

BLU

Industry Average

Valuation BLU Industry Range
No financial data is available for BLU.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BELLUS HEALTH INC, please visit www.bellushealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.